O-(2-18F-氟乙基)-L-酪氨酸PET在脑干和脊髓胶质瘤诊断中的应用
本研究在29例脑干或脊髓胶质瘤患者中完成36次18F-FET PET扫描,其中32次行动态采集,用于新诊断、肿瘤进展诊断及治疗监测;最终诊断经组织学(54%)或临床随访(46%)确认。新诊断高级别胶质瘤3例均见18F-FET摄取增高,低级别11例中5例摄取增高;疑似进展时TBR与动力学参数联合在11例中正确判断9例(82%)。
要点
- 新诊断高级别胶质瘤3例18F-FET摄取均增高(TBRmax≥2.5和/或TBRmean≥1.9)。
- 新诊断低级别胶质瘤11例中5例18F-FET摄取增高。
- 疑似进展时TBR联合动力学参数在11例中正确判断9例(82%)。
核心结论
- 这项初步研究提示,18F-FET PET可为脑干和脊髓胶质瘤提供有价值的诊断信息,尤其当MRI所得诊断信息不明确时。
研究设计与样本
- 在29例脑干(29次扫描)或脊髓(7次扫描)胶质瘤患者中完成36次18F-FET PET扫描,32次行动态采集。
- 15例15次扫描用于评估新诊断病灶;21次扫描用于随访,其中诊断肿瘤进展15次扫描(14例)、治疗监测6次扫描(3例)。
- 4例患者接受额外序列扫描(范围1-2次),其中3例因一个以上指征接受检查;最终诊断经组织学(54%)或临床随访(46%)确认。
主要发现
- 新诊断高级别胶质瘤3例均见18F-FET摄取增高(TBRmax≥2.5和/或TBRmean≥1.9);新诊断低级别胶质瘤11例中5例摄取增高。
- 2例新诊断胶质瘤无MR对比增强,但18F-FET PET显示代谢增高。
- 疑似进展时,TBR联合动力学18F-FET参数在11例中正确识别进展性疾病存在与否9例(82%)。
关键数值与推荐
- 18F-FET摄取采用注射后20-40分钟的最大和平均肿瘤/脑比值(TBRmax/TBRmean)及动力学参数评估。
- 摄取增高判定标准为TBRmax≥2.5和/或TBRmean≥1.9。
临床怎么用
- 作者认为18F-FET PET可为脑干和脊髓胶质瘤提供有价值的诊断信息,尤其当MRI诊断信息不明确时。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite an increasing number of O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) PET studies in supratentorial gliomas, studies regarding the usefulness of 18F-FET PET in brainstem and spinal cord gliomas to date remain scarce. METHODS: Thirty-six 18F-FET PET scans were performed in 29 patients with brainstem (n = 29 scans) or spinal cord glioma (n = 7 scans). In 32 of 36 PET scans, a dynamic acquisition was performed. Fifteen scans in 15 patients were performed to assess newly diagnosed lesions, and 21 scans were obtained during follow-up: for diagnosing tumor progression (n = 15 scans in 14 patients) as well as for treatment monitoring (n = 6 scans in 3 patients). Four patients underwent additional serial scans (range, 1-2), and 3 of these 4 patients were examined for more than one indication. Maximum and mean tumor/brain ratios (TBRmax/mean) of 18F-FET uptake (20-40 min post injection) as well as kinetic 18F-FET uptake parameters were determined. Final diagnoses were confirmed histologically (54%) or by clinical follow-up (46%). RESULTS: In all newly diagnosed high-grade (n = 3 patients) and in 5 of 11 patients with low-grade gliomas, 18F-FET uptake was increased (TBRmax ≥2.5 and/or TBRmean ≥1.9). In 2 patients with newly diagnosed gliomas without MR contrast enhancement, 18F-FET PET nevertheless showed increased metabolism. At suspected progression, the combination of TBRs with kinetic 18F-FET parameters correctly identified presence or absence of progressive disease in 9 of 11 patients (82%). CONCLUSIONS: This preliminary study suggests that 18F-FET PET adds valuable diagnostic information in brainstem and spinal cord glioma, particularly when the diagnostic information derived from MRI is equivocal.
引用
- Tscherpel C, Dunkl V, Ceccon G, et al. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord. Neuro Oncol. 2017. PMID: 28039366. doi:10.1093/neuonc/now243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。